deferiprone has been researched along with Retinal Degeneration in 6 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 7.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 3.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| " Dosing with DFP protected photoreceptors, decreasing the numbers of TUNEL-positive photoreceptors and increasing the number of surviving photoreceptors." | 1.38 | Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina. ( Dunaief, JL; Hadziahmetovic, M; Song, D; Song, Y; Zhong, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Boyd, P | 1 |
| Hyde, DR | 1 |
| Cui, QN | 1 |
| Bargoud, AR | 1 |
| Ross, AG | 1 |
| Song, Y | 4 |
| Dunaief, JL | 4 |
| Song, D | 2 |
| Zhao, L | 1 |
| Li, Y | 1 |
| Hadziahmetovic, M | 3 |
| Connelly, J | 2 |
| Spino, M | 2 |
| Shirai, Y | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Sakamoto, K | 1 |
| Ishii, K | 1 |
| Wolkow, N | 1 |
| Iacovelli, J | 1 |
| Grieco, S | 1 |
| Lee, J | 1 |
| Lyubarsky, A | 1 |
| Pratico, D | 1 |
| Harris, ZL | 1 |
| Zhong, Y | 1 |
6 other studies available for deferiprone and Retinal Degeneration
| Article | Year |
|---|---|
Iron contributes to photoreceptor degeneration and Müller glia proliferation in the zebrafish light-treated retina.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Cell Proliferation; Deferiprone; Ependymoglial Ce | 2022 |
Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma.
Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Female; Glaucoma; Iron Chelating | 2020 |
The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Electroretinography; Ferritins; | 2014 |
Deferiprone Protects against Photoreceptor Degeneration Induced by Tunicamycin in the Rat Retina.
Topics: Animals; Deferiprone; Electroretinography; Iron Chelating Agents; Male; Protective Agents; Pyridones | 2015 |
The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.
Topics: Administration, Oral; Animals; Antigens, CD; Cell Death; Cell Line; Ceruloplasmin; Deferiprone; Elec | 2011 |
Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina.
Topics: Animals; Apoptosis; Deferiprone; Female; Fluorescent Antibody Technique; In Situ Nick-End Labeling; | 2012 |